Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Investigating the Prevalence of Psychiatric Disorders in Multiple Sclerosis with Autoimmune Comorbidities
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
3-008

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that has a high prevalence of autoimmune and psychiatric comorbidities. Previous studies have not addressed how these comorbidities in MS relate to each other.

To assess the relationship between comorbid autoimmune diseases (ADs) and psychiatric disorders among patients with MS, and to elucidate possible environmental factors or health disparities within this relationship.

A retrospective case-control study was conducted using patient records from Hawaii with a diagnosis of MS from January 2000 to June 2022. Sociodemographic variables, clinical characteristics, and comorbidities were collected. Variables between the AD status groups were compared using the Wilcoxon rank sum test for continuous variables and Pearson’s Chi-squared test or Fisher’s exact test for categorical variables. A p-value less than 0.05 was considered statistically significant.

Of the 105 patients with MS analyzed, 28% (n=30) had comorbid ADs. The proportion of the type Primary Progressive MS among them was higher, compared to patients without ADs (30.8% vs. 11.1%; p = 0.030). They were also found to have a significantly higher prevalence of depression (50% vs. 25%; p = 0.015) and, although not significant, anxiety (30% vs. 21%; p=0.35), compared to the group without ADs. Comorbid ADs in MS did not seem to be associated with sociodemographic factors, but did appear to be associated with a significantly higher prevalence of health disparities, such as asthma (26.7% vs. 10.7%; p=0.067) and coronary artery diseases (13.3% vs. 2.7%; p=0.054).

Our findings suggest that comorbid ADs are associated with increased risks of depression and other debilitating health disparities among patients with MS. This result can influence treatment options and inter-specialty care management to improve the outcomes in MS patients with comorbid ADs.

Authors/Disclosures
Shin Chang
PRESENTER
Ms. Chang has nothing to disclose.
Plyfaa Suwanamalik-Murphy Ms. Suwanamalik-Murphy has nothing to disclose.
Jenna Okazaki Miss Okazaki has nothing to disclose.
Donovan Roy Mr. Roy has nothing to disclose.
Masako Matsunaga (University of Hawaii at Manoa) Masako Matsunaga has nothing to disclose.
Connor Goo Mr. Goo has nothing to disclose.
Enrique Carrazana Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Neurelis, Alexza, Zogenix. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences. Enrique Carrazana has stock in Neurelis, Marinus, .
Jason Viereck, MD, PhD (Adventist Health Castle Hospital) Dr. Viereck has nothing to disclose.
Kore K. Liow, MD, FACP (University of Hawaii, John Burns School of Medicine) The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.